Summary Results Of Phase 1 Metastatic Melanoma Study Released By Provectus Pharmaceuticals, Inc.

Provectus Pharmaceuticals, Inc. (OTCBB: PVCT) announced preliminary results of its Phase 1 clinical trial of Provecta for the treatment of metastatic melanoma, the most aggressive form of skin cancer. Provecta demonstrated minimal side effects, significant efficacy and bystander effect on melanoma tumors in stage III patients. The study evaluated safety and efficacy of Provecta in a total of 20 subjects at two sites in Australia. [click link for full article]

More: continued here

Filed under: Cancer on September 20th, 2007